iiinova — where your digital self keeps evolving

GoggleDocs

@goggledocs.bsky.social

189 followers 179 following 84 posts

Docs/nurses/pharmacists from U.K. Talking CardioRenoMetabolic (#CaReMe) & more Catch us on YouTube youtube.com/c/GoggleDocs |Educate, Motivate, Activate!

Posts Replies Media

GoggleDocs @goggledocs.bsky.social · 10/05/2025

📢 TyG-BMI: a new vital sign in #MASLD? 🔹 NHANES study: TyG-BMI ⤴️ = ⤴️ all-cause ☠️ & 💔☠️ 🔸 U-shaped risk curve—both high & low TyG-BMI = ⤴️ risk 🔹 HbA1c mediated most of the effect 👉 For MASLD, insulin resistance isn’t just present—it’s predictive❗️ 🔗 ggdocs.co/9cu63n @pharmrj.pharmsky.app

Reposted by GoggleDocs

Kevin Fernando @drkevinfernando.bsky.social · 01/05/2025

🚦Updated @medscape.com Primary Care #Hack 🔥Interpreting iron studies in primary care🔥 🎯 What are iron studies? 🎯 Top tips & pitfalls to avoid 🎯 Managing ⬆️ ferritin 🎯 Iron deficiency: once daily dosing help absorption PDF download link in comments 👇🏾 @goggledocs.bsky.social @pharmrj.pharmsky.app

Reposted by GoggleDocs

Kevin Fernando @drkevinfernando.bsky.social · 02/05/2025

🚦Latest @medscape.com Primary Care #hack is live! 🔥Paired #hacks covering the diagnosis & management of #HFrEF & #HFpEF in primary care PDF download link in comments 👇🏾 @pharmrj.pharmsky.app @goggledocs.bsky.social @hpillminster.pharmsky.app

GoggleDocs @goggledocs.bsky.social · 02/05/2025

📢 Can LFTs track liver fat loss after weight loss in #T2D❓ 🔹 DiRECT sub-study: 74% achieved MASLD remission with ~12kg wt loss 🔸 ⤵️ ALT & GGT= predictors of liver fat ⤵️ (ALT >40 = PPV 100%) 🔹 ALT change most closely linked to liver fat ⤵️ 👉LFTs = simple tool to track remission 🔗 ggdocs.co/9g8ffo

GoggleDocs @goggledocs.bsky.social · 30/04/2025

Who’s getting #GLP1 for #obesity 🇺🇸❓ 🔹 <3% of 39M eligible pts got Sema/tirz 🔸 ⚫️⚪️ ⚠️ Px lower in ♂️, ⚫️/Asian/Hispanic pts, high SVI & rural area 🔹 Uptake ⤴️ overall, but disparities persist 🔸 Reflects system-level barriers 👉 #ObesityCare evolving—equity must catch up❗️ 🔗 ggdocs.co/ao046p

000

Reposted by GoggleDocs

Kevin Fernando @drkevinfernando.bsky.social · 29/04/2025

🔥Our #CVRMUK paper is now published! 💡"Advancing Cardiovascular, Kidney, and Metabolic Medicine: A Narrative Review of Insights and Innovations for the Future" 🎯This review advocates for an integrated #CKM framework Open access link in comments 👇🏾 @goggledocs.bsky.social @pharmrj.pharmsky.app

GoggleDocs @goggledocs.bsky.social · 15/04/2025

📢 Danuglipron dropped—can orforglipron still be the “oral GLP-1 that delivers”? 🔹 Pfizer halts danuglipron after liver signal 🔸 Orforglipron P2=HbA1c ⤵️2.1%, Wt ⤵️14.7%, no liver signal 🔹 P3 2025—will it safely deliver? 👉 Small molecule GLP-1: blockbuster or cautionary tale? 🔗 ggdocs.co/5qu8y3

Reposted by GoggleDocs

Kevin Fernando @drkevinfernando.bsky.social · 27/03/2025

Hot on heels of CVRMUK congress, @EimearDarcy & I present our updated @medscape.com Primary Care #Hack 🔥#T2D #CVRM checklist🔥 💡A holistic, person-centred approach to supporting our patients living with #T2D PDF download in comments below👇🏾 @goggledocs.bsky.social @pharmrj.pharmsky.app

Reposted by GoggleDocs

Kevin Fernando @drkevinfernando.bsky.social · 24/03/2025

🎯 CVRMUK London conference tomorrow! I'm covering 💡A history lesson: the evolution of cardio-renal disease 💡The intersection of sleep & #CVRM 💡EASL-EASD-EASO #MASLD guidance 🔥 Our Autumn CVRMUK conference is on 26/11/25 Register 👇🏾 @goggledocs.bsky.social @pharmrj.pharmsky.app

Reposted by GoggleDocs

Prof Derek Connolly @profderekconnolly.bsky.social · 22/03/2025

🌍 Our real-world paper shows GLP1s are associated with lower risk of MACE & less costs than DPP4s or insulin in T2DM at higher CV risk 💔 link.springer.com/article/10.1... @pccs.bsky.social @goggledocs.bsky.social @sabouretcardio.bsky.social @astonuniversity.bsky.social @swbhnhs.bsky.social

link.springer.com

Real-World Comparisons Between Glucagon-Like Peptide-1 Receptor Agonists and Other Glucose-Lowering Agents in Type 2 Diabetes: Retrospective Analyses of Cardiovascular and Economic Outcomes in England...

Introduction Clinical trials have demonstrated that glucagon-like peptide-1 receptor agonists (GLP-1RAs) reduce the risk of major adverse cardiovascular events (MACE) in adults with type 2 diabetes (T...

GoggleDocs @goggledocs.bsky.social · 22/03/2025

📢 #GLP1 ⤵️ kidney decline, CV events & mortality in CKD❗️ 🔹 Meta-analysis of 18K pts w/ eGFR <60: ⤵️ eGFR decline ≥50% (OR 0.72) ⤵️ 💔 (OR 0.86) ⤵️ ☠️ (OR 0.77) 🔸 ⤵️⤵️ with human GLP-1 backbone 🥇Evidence across CKD stages—not just macroalbuminuria 👉 GLP-1 now a key 🎯 in CKD + #T2D 🔗 ggdocs.co/tnqomz

GoggleDocs @goggledocs.bsky.social · 21/03/2025

Oral semaglutide cost-effective vs. liraglutide—even at 50% ⤵️ price 🔹 🇬🇧 modelled data: ⤴️ QALYs (+0.18) & ⤵️ comp. 🔸 💊 = ⤵️ Rx burden vs. daily 💉 🔹 Results robust across sensitivity analyses ⚠️ funded by NovoNordisk 👉 Challenges low-cost liraglutide, supports 🎯 oral GLP-1 use 🔗 ggdocs.co/9h0bz1

Reposted by GoggleDocs

Kevin Fernando @drkevinfernando.bsky.social · 17/03/2025

🎯Updated @medscape.com Primary Care #Hack 🔥 #DOAC dosing for stroke prevention in #NVAF & kidney impairment🔥 🚨 #DOACs are not "fire & forget" drugs 💡 Do not use #eGFR; #CrCl should be used for drug dosing PDF download link in comments below 👇🏾 @goggledocs.bsky.social @pharmrj.pharmsky.app

GoggleDocs @goggledocs.bsky.social · 16/03/2025

📢 ACR in Obesity (Ob): Are we under Dx albuminuria? 🔹 Ob ⤴️ creatinine excretion = ACR underestimates albuminuria 🔸 Delay Rx in #CKD & #T2D—esp. RASi, SGLT2i, nsMRA 🔹 Bias = in ♂ & ⤴️ muscle 🔸 Review calls➡️♀️♂️ cutoffs or estimated AER (eAER) 🕓 to rethink ACR thresholds in Ob❓ 🔗 ggdocs.co/l1htvt

000

GoggleDocs @goggledocs.bsky.social · 14/03/2025

Albuminuria: The CKM biomarker we’re overlooking❗️ 🥇 risk biomarker 🔹 Even UACR <3.4 mg/mmol = ⤴️ #CVD, #CKD & ☠️ risk 🔸 Signals early endothelial dysfunc. in HTN, #T2D, #HF & #MASLD 🔹 Yet 💧screening rates low 🔸 Newer Rx (SGLT2i, #GLP1 , nsMRA) = 🎯 ⌛detect, disclose & treat❗️ 🔗 ggdocs.co/hot30b

GoggleDocs @goggledocs.bsky.social · 12/03/2025

GLP-1 & blood cancer risk: Encouraging signal in cohort study 🔹 #T2D patients on GLP-1 ⤵️ risk vs. insulin for hematological cancers (HR 0.46) 🔸 ⤵️ risk of MDS, MPN, leukaemia, lymphoma & myeloma 🔹 No benefit vs. met 🔸 ⚠️ RWD = unresolved bias 👉 Supports 🎯 trials ⤵️cancer 🔗 ggdocs.co/3yosuj

Reposted by GoggleDocs

Kevin Fernando @drkevinfernando.bsky.social · 10/03/2025

💡 My latest Medical Mentor podcast is live! 🔥Interpretation & management of hypocalcaemia for PC 🔥 On Spotify, Apple Podcasts & Medscape website (link👇🏾) +see my @medscape.com PC #Hack on hypercalcaemia and hypocalcaemia in PC (link👇🏾) @goggledocs.bsky.social @pharmrj.pharmsky.app

Reposted by GoggleDocs

Dr Hema Chaplin @hemachaplin.bsky.social · 07/03/2025

📢 Are you a #UK #HealthcareProfessional managing patients with #KidneyDisease, #HighBloodPressure, #Diabetes or #Lupus? 👩‍⚕️ We want to hear what information/education you deliver about #kidneys, & anything that helped or hindered you. 🔗 app.onlinesurveys.jisc.ac.uk/s/salford/ph... 🙌 Thank you!

GoggleDocs @goggledocs.bsky.social · 05/03/2025

#Finerenone: CV & renal protection across all #T2D therapies❗️ 🔹 Pooled analysis: 15,365 pts w/ T2D + CKD or CV 🔸 Consistent benefit on 💔☠️, 🏥💔& kidney outcomes 🔹 ⤴️K+ ⤵️ with SGLT2i use 🔸 Benefit independent of SGLT2i/GLP-1 use 👉 Supports finerenone as a 🎯 in high-risk #T2D❗️ 🔗 ggdocs.co/tx2a5r

GoggleDocs @goggledocs.bsky.social · 28/02/2025

📢 #T1D Closed-Loop: MiniMed™ 780G in Real-World France 🔹 TIR ⤴️ 11.8% (2.8h/day) at 6m, HbA1c ⤵️ 0.52% 🔸 Hypoglycemia risk ⤵️, zero severe hypos @ 12m 🔹 Diabetes distress ⤵️ & QoL ⤴️ in adults & teens 🔸 Fear of hypos ⤵️ in adults & children 👉 HCL the new standard in #DiabetesCare❗️ 🔗 ggdocs.co/pwpsiu

GoggleDocs @goggledocs.bsky.social · 27/02/2025

📢 Mediterranean Diet: A Recipe for Cancer Prevention? 🇬🇧1 in 10 cancers - Obesity related (ORC) 🔹 n450,111, 15y follow-up in EPIC study 🔸 6% ⤵️ risk ORC withMedDiet adherence (HR 0.94) 🔹 Colorectal, liver, kidney cancer ⤵️ 🔸 Not weight—no mediation via BMI/waist-to-hip ratio 🔗 ggdocs.co/7larkw

GoggleDocs @goggledocs.bsky.social · 27/02/2025

MASLD: ‘Elephant in the Room’ of #CKM 🔹 🌍 crisis: 1/3 adults affected, 65% in #T2D 🔸 Liver fibrosis=predictor of ☠️ & #CVD, #CKD,&HCC 🔹 No approved Rx – 🎯 lifestyle, ⤵️weight & multi-specialty care 🔸 Future hope: GLP-1s, PPAR, THR-β agonists 👉 Access the full paper via link 🔗 ggdocs.co/dz0kai

GoggleDocs @goggledocs.bsky.social · 26/02/2025

📢 #GLP1 & Safety: 82 Deaths Reported 🇬🇧 🔹 60 deaths linked to #T2D use, 22 to weight loss 🔸 Mounjaro (18), Ozempic/Wegovy (29), Victoza/Saxenda (35) ⚠️Reports ≠ causation, but raises need for better patient education 👉MHRA warns against unregulated online sales & fake pens 🔗 ggdocs.co/oapff4

GLP-1 agonists: 82 deaths linked to adverse reactions, UK data show

Data submitted to the UK drugs regulator show a total of 82 deaths related to glucagon-like peptide-1 receptor agonists, the class of drugs used for weight loss and type 2 diabetes. Data from the yel...

000

GoggleDocs @goggledocs.bsky.social · 26/02/2025

"Computer says yes" to help pick the best glucose-lowering drug #T2D 🔹 Machine-learning predicts optimal therapy (GLP1, SGLT2i, SU, DPP4i, or TZD) 🔸 Model-concordant Rx = 5.3 mmol/mol ⤵️ HbA1c at 12m 🔹 Better long-term outcomes: 38% ⤵️ glycaemic failure, 29% ⤵️ renal risk, 15% ⤵️ 💔 🔗 ggdocs.co/9p2tgf

A five-drug class model using routinely available clinical features to optimise prescribing in type 2 diabetes: a prediction model development and validation study

We have developed a five-drug class model that uses routine clinical data to identify optimal glucose-lowering therapies for people with type 2 diabetes. Individuals on model-predicted optimal therapy...

000

GoggleDocs @goggledocs.bsky.social · 24/02/2025

📢 Beyond GLP-1: The next wave ... 🔹 GIP/GLP-1 dual agonists (e.g., #Tirzepatide) ⤴️ wt loss vs. GLP-1 🔸 3x agonists (GIP/GLP-1/Glucagon) aim for >25% wt loss 🔹 Emerging 💉💊: Amylin + GLP-1 combos, FGF21 analogs, oral non-peptides 👉 Will the next-gen 💉 ⤴️ wt loss beyond 30%❓ 🔗 ggdocs.co/hefyaj

GoggleDocs @goggledocs.bsky.social · 23/02/2025

Can resistance exercise reverse frailty in #T2D ❓ 🔹 Frailty ⤵️ in 36% of intervention group vs. 17% usual care (OR 2.6, p=0.009) 🔸 SPPB ⤴️ by 1+ point in 47.8% vs. 35.3% (p=0.034) 🔹 Early intervention key❗️ 👉 Time to rethink exercise as standard Rx for frailty in #T2D 🔗 ggdocs.co/zvm0cn

000

GoggleDocs @goggledocs.bsky.social · 21/02/2025

📢 Cardiac, Renal & Metabolic (CRM) Overlap: A Public Health Crisis? 🔹 CRM multimorbidity ⤴️ in 20 yrs (1 CRM: 21% → 26%, all 3: 0.7% → 1.5%) 🔸 ⚫️ & low SES = ⤴️ risk but ⤵️treatment❗️ 🔹 Statins underused in 1/3 CRM pts, ACEi/ARB in 40-50%, SGLT2i/GLP1 <5% 👉 MDT + 🎯 therapy= key❗️ 🔗 ggdocs.co/enhs7v

GoggleDocs @goggledocs.bsky.social · 19/02/2025

A ☕ a day helps keep the cirrhosis away❓ 🔹 78mg+ daily linked to ⤵️ liver fibrosis risk in #T2D, prediabetes & normoglycemia 🔸 Effect independent of BMI, SES, etc... 🔹 T2D strongest benefit 🔸 No evidence that fancy oat milk lattes offer extra 😉 👉 ☕✅ @pharmrj.pharmsky.app 🔗 ggdocs.co/vcwmxp

Caffeine intake associated with a lower risk of liver fibrosis in different glucose status

To investigate the prevalence of liver fibrosis, and the association between caffeine intake and fibrosis in populations with different glucose metabo…

Reposted by GoggleDocs

Kevin Fernando @drkevinfernando.bsky.social · 19/02/2025

#SGLT2is are therapeutic titans but no drug is without harm My #SGLT2i resources to ensure benefits outweigh harms: 🎯 Patientfacing YouTube videos youtube.com/@drkevinfern... 🎯 @medscape.com Primary Care #Hacks www.medscape.co.uk/viewarticle/... @goggledocs.bsky.social @pharmrj.pharmsky.app

GoggleDocs @goggledocs.bsky.social · 18/02/2025

GLP-1RAs: Potential in Mental Health? 🔹 Systematic Review 🔸 Cognitive disorders: ⤵️ dementia risk in #T2D 🔹 Substance use: ⤵️ alcohol & nicotine use via dopamine pathways 🔸 Mood & psychotic disorders: No clear benefit, 👉 GLP-1RAs show promise but need RCTs in mental health❗️ 🔗 ggdocs.co/b41wuf

An analysis on the role of glucagon-like peptide-1 receptor agonists in cognitive and mental health disorders - Nature Mental Health

De Giorgi and colleagues present a comprehensive analysis of pre-clinical and clinical studies examining the role of glucagon-like peptide-1 receptor agonists in mental disorders.

Reposted by GoggleDocs

Kevin Fernando @drkevinfernando.bsky.social · 10/02/2025

🔥 Updated @medscape.com Primary Care #Hack use of liraglutide semaglutide & tirzepatide for adults living with overweight & obesity 🔥 🎯 Elective peri-operative management consensus 🎯Language matters: obesity & specific conversation techniques PDF download link in comments @goggledocs.bsky.social

GoggleDocs @goggledocs.bsky.social · 10/02/2025

Can #GLP1 & #SGLT2i ⤵️ #COPD Exacerbations❓ 🔹 SGLT2i vs DPP4i: ⤵️ 19% risk of moderate/severe exacerbations 🔸 GLP-1RA vs DPP4i: ⤵️ risk by 14% 🔹 SGLT2i vs GLP-1RA: No major difference (HR 0.94) ❓Biological mechanisms 🤔 ⚠️ Observational data 👉 Interesting, but RCTs needed‼️ 🔗 ggdocs.co/v7zkht

Glucose-Lowering Medications and Risk of Chronic Obstructive Pulmonary Disease Exacerbations in Type 2 Diabetes

This comparative effectiveness research study examines the outcomes of treatment with sodium-glucose cotransporter-2 inhibitors, glucagon-like peptide-1 receptor agonists, or dipeptidyl peptidase-4 in...

000

GoggleDocs @goggledocs.bsky.social · 05/02/2025

#CGM vs. SMBG: Cost-Effectiveness of FreeStyle Libre in 🇨🇦 🔹 More QALYs, lower cost vs. SMBG in #T1D & #T2D 🔸 T1D: +1.25 QALYs, ⤵️ cost (🇨🇦$32,287) 🔹 T2D: +0.48 QALYs, ⤵️ cost (🇨🇦$8091) 🔸 Absenteeism ⤵️ = key driver of 💰 savings 👉 CGM cost effective in 🇨🇦 🔗 ggdocs.co/w8caj3 @pharmrj.pharmsky.app

Cost-Effectiveness of FreeStyle Libre for Glucose Self-Management Among People with Diabetes Mellitus: A Canadian Private Payer Perspective - Diabetes Therapy

Introduction For people living with diabetes, effective glucose monitoring is a key component in diabetes care, helping to reduce disease burden, complications, and healthcare utilization. Sensor-base...

GoggleDocs @goggledocs.bsky.social · 05/02/2025

Real-world tirzepatide use in #T2D in 🇺🇸 🔹 Initiation: 84% start at ≤5 mg, 69.6% ⤴️ dose within 6m 🔸 Dosing at 6m: 56.5% remain <10 mg 🔹 Persistence: 73.3% still on treatment at 6m 🔸 Discontinuation: 26.7% stopped, 29.1% restarted 👉 Persistence high, slower titration the norm 🔗 ggdocs.co/0z0q43

GoggleDocs @goggledocs.bsky.social · 04/02/2025

Dexcom ONE in insulin-treated #T1D & #T2D 🔹 HbA1c⤵️ at 6m: T1D (-12 mmol/mol) & T2D (-18) 🔸 TIR⤴️ in T2D (+9%) = 2.2h/day in range 🔹 Diabetes distress ⤵️ (71%→42% in T1D, 51%→31% in T2D) 🔸 🎯 for deprived areas (41% T2D in lowest SES quintile) 👉 Works in deprived area🇬🇧❗️ 🔗 ggdocs.co/tpevdz

<em>Diabetic Medicine</em> | Diabetes UK Journal | Wiley Online Library

Aims This study assessed real-world glycaemic outcomes associated with the use of Dexcom ONE in adults with suboptimally controlled diabetes. Methods In this single-site prospective study, adults ...

Reposted by GoggleDocs

Kevin Fernando @drkevinfernando.bsky.social · 03/02/2025

My latest @medscape.com Primary Care #Hack is live! Co-authored with #CVRM guru Niraj Lakhani 🔥Lipid management for primary & secondary prevention of #CVD🔥 🎯10 key principles, 10 deeper dives & a flowchart! PDF weblink in comments. @pharmrj.pharmsky.app @goggledocs.bsky.social

GoggleDocs @goggledocs.bsky.social · 03/02/2025

📢 #GLP1 in overweight/obesity—who stops & who restarts? 🔹 1-year disc.: #T2D 46.5% ⤵️ vs. no T2D 64.8% ⤴️ 🔸 1-year reinitiation: #T2D 47.3% ⤴️ vs. no T2D 36.3% ⤵️ 🔹 ⤴️Wt loss ⤵️disc. risk 🔸 GI AEs ⤴️ disc. risk (HR 1.38 in T2D, 1.19 no T2D) 👉 💰& 🤢 drive inequities in long-term❗️ 🔗 ggdocs.co/456b83

000

GoggleDocs @goggledocs.bsky.social · 31/01/2025

“#Ozempic babies”: Fact or Fiction? 🔹 No clear evidence from clinical data 🔸 Wt loss ⤴️ fertility in PCOS, but impact on oral contraceptive absorption unclear 🔹 May ⤵️ oral contraception via delayed gastric emptying 🔸💉makers advise contraception & stopping meds 2m pre-conception 🔗 ggdocs.co/otufnr

Ozempic babies: are weight loss drugs leading to unintended pregnancies?

Posts about unexpected pregnancies while using drugs such as Ozempic for weight loss are trending on social media. Does any scientific evidence back this up? Sangeetha Nadarajah reports Amid the risi...

000

GoggleDocs @goggledocs.bsky.social · 30/01/2025

📢 🏴󠁧󠁢󠁥󠁮󠁧󠁿 Goverment briefing #weightloss 💉 🔹 Now NHS-approved for BMI ≥35 related comorbidity 🔸 Lower BMI thresholds for non ⚪️populations 🔹 NHS rollout phased—90d specialist services, ⤵️ 12y for all 🔸 Concerns: capacity & £15.2B cost 👉 NHS wt loss pathways need urgent expansion! 🔗 ggdocs.co/4aohcm

Weight loss medicines in England

A briefing on the licensing, regulation and supply of new weight loss medications in England.

GoggleDocs @goggledocs.bsky.social · 29/01/2025

Ethnicity & Socioeconomic Status (SES) in #T2D Microvascular dis. #SystematicReview 🔹 CKD: 18% prev —no ethnic diff, but ⤵️ SES = ⤴️ risk 🔸 👁️(DR): ⚫️ 28% > SAsian 25% > ⚪️ 19% 🔹 Low SES = ⤴️ DR (25% v 16%) 🔸 Progression risk: ⚫️ ethnicity = ⤴️ ESRD & 👁️ 👉 Need 🎯of high-risk groups❗️ 🔗 ggdocs.co/q0jhsx

The Prevalence and Progression of Microvascular Complications and the Interaction With Ethnicity and Socioeconomic Status in People With Type 2 Diabetes: A Systematic Review and Meta‐Analysis

Introduction: Diabetic nephropathy (DN) and diabetic retinopathy (DR) are serious complications of type 2 diabetes mellitus (T2DM). The reported estimates of prevalence and progression of DN and DR v...

000

Reposted by GoggleDocs

Helen Hương Kilminster @hpillminster.pharmsky.app · 29/01/2025

This looks interesting 🤨 The dementia screening profile of bloods on ICE (our path ordering system) could be expanding to include bio markers?! One for @goggledocs.bsky.social & @drkevinfernando.bsky.social 🤓

GoggleDocs @goggledocs.bsky.social · 26/01/2025

Oral semaglutide in #T2D: Real-world results from 7 countries 🇨🇦🇩🇰🇮🇹🇳🇱🇸🇪🇨🇭🇬🇧 🔹 HbA1c ⤵️ 1.0%, Wt ⤵️ 5.0% at 38w 🔸 Greater benefits in early T2D: HbA1c ⤵️ 1.7%-points if <1 year duration. 👉 Treatment satisfaction ↗️ sig. ❗️Safe, effective across ages, settings. 🔗 ggdocs.co/ussdr9 @pharmrj.pharmsky.app

Oral Semaglutide Use in Type 2 Diabetes: A Pooled Analysis of Clinical and Patient-Reported Outcomes from Seven PIONEER REAL Prospective Real-World Studies - Diabetes Therapy

Introduction Oral semaglutide is a glucagon-like peptide 1 receptor agonist (GLP-1RA) approved for improving glycemic control in adults with type 2 diabetes (T2D). The PIONEER REAL program evaluates c...

GoggleDocs @goggledocs.bsky.social · 26/01/2025

EASO 🔥 Critiques Lancet’s #Obesity Framework 🇪🇺 🔹“Preclinical obesity” = delayed care 🚨 🔸Ignores T2D evidence (treatment ⤵️ complications) 🔹Flawed metrics: BMI focus ❌, misses root causes 👉 EASO’s fix: ✅ Early intervention ✅ WtHR + biology ✅ Equity > BMI 🔗 ggdocs.co/u5d8il

GoggleDocs @goggledocs.bsky.social · 26/01/2025

Dapagliflozin + calorie restriction: A new pillar in #T2D remission? 🇨🇳 🔹 RCT: 44% achieved remission vs. 28% placebo (RR 1.56, 95% CI 1.17-2.09). 🔸 Key stats: –1.3 kg weight difference, ⤵️ insulin resistance 👉 Alternative strategy for early diabetes—long-term sustainability❓ 🔗 ggdocs.co/i51w3p

Dapagliflozin plus calorie restriction for remission of type 2 diabetes: multicentre, double blind, randomised, placebo controlled trial

Objective To assess the effect of dapagliflozin plus calorie restriction on remission of type 2 diabetes. Design Multicentre, double blind, randomised, placebo controlled trial. Setting 16 centres i...

GoggleDocs @goggledocs.bsky.social · 25/01/2025

GLP-1 agonists: A potential game-changer for childhood #obesity ❓ 🔹 In trials, semaglutide reduced BMI by 16.1% in adolescents over 68 weeks vs. 0.6% with placebo. 🔸 Access remains limited, but early results show promise for managing youth. ❗️Long-term studies are needed❗️ 🔗 ggdocs.co/kijcvk

Can weight loss drugs like Ozempic treat obesity in children?

GLP-1 agonists for weight loss are now commonly used for adults, but might they also be an effective treatment for younger people? Katharine Lang reports Obesity in children and adolescents is a grow...

GoggleDocs @goggledocs.bsky.social · 25/01/2025

Finerenone in HFpEF/HFmrEF ❗️ 🔹 Early eGFR declines (≥15%) with finerenone are common (23% vs. 13% placebo). 🔸 Unlike placebo, these declines were not associated with worse outcomes. 🔹 Finerenone ⤵️ 💔 & CV ☠️across eGFR changes. ❗️Don’t stop finerenone due to early eGFR dips❗️ 🔗 ggdocs.co/3w7mim

GoggleDocs @goggledocs.bsky.social · 24/01/2025

Amycretin: “New kid on the block”❓ 🔹 Phase 1b/2a trial shows amycretin, a dual GLP-1/amylin receptor agonist ⤵️ body weight by up to 22% over 36 weeks. 🔸 Safety profile consistent with incretin therapies, with mild GI side effects. ❗️A promising therapy for #obesity & #T2D. 🔗 ggdocs.co/qjg1lw

GoggleDocs @goggledocs.bsky.social · 22/01/2025

Is ASC30 (small molecule #GLP1) the most promising❓ ⚠️ Early P1 trial results ✅ long half-life (60h) 🔹Tolerability "consistent with or better than others" 🔸In-vitro ASC30 👉 2-3x potent to orforglipron 👉 Competition should ⤵️ price of this class 🔗 ggdocs.co/gtcv6u @pharmrj.pharmsky.app

Ascletis Announces Positive Results from U.S. Phase Ia Single Ascending Dose Study of Small Molecule Oral GLP-1R Agonist ASC30 and Provides Program Update

ASC30 oral tablet demonstrated dose-proportional pharmacokinetic (PK) properties and a long half-life (t1/2) up to 60 hours in the single ascending dose (SAD)...

GoggleDocs @goggledocs.bsky.social · 21/01/2025

Finerenone: Do we need another treatment for #CKD in #T2D ❓ 🔹 Reduces CKD progression by 23% & CV events by 14% (FIDELITY analysis). 🔸 Complements RASi & SGLT2i therapies, offering comprehensive cardio-renal protection. ❗️A new pillar in T2D & CKD Mx #CombinationTherapy. 🔗 ggdocs.co/nqip3c

000

GoggleDocs @goggledocs.bsky.social · 20/01/2025

IGFBP7: a novel target for #T2D therapy❗️ 🔹 Elevated in T2D islets, IGFBP7 reduces insulin secretion via impaired mitochondrial function. 🔸 Knockdown of IGFBP7⤴️ insulin secretion in human islets by 30%. ❗️Emerging as a potential multi-tissue drug target for T2D etc.. 🔗 ggdocs.co/jk9qlo

IGFBP7 is upregulated in islets from T2D donors and reduces insulin secretion

Physiology; Cellular physiology; Cell biology

000